PL2861240T3 - Kwasy nukleinowe do leczenia alergii - Google Patents

Kwasy nukleinowe do leczenia alergii

Info

Publication number
PL2861240T3
PL2861240T3 PL12878776T PL12878776T PL2861240T3 PL 2861240 T3 PL2861240 T3 PL 2861240T3 PL 12878776 T PL12878776 T PL 12878776T PL 12878776 T PL12878776 T PL 12878776T PL 2861240 T3 PL2861240 T3 PL 2861240T3
Authority
PL
Poland
Prior art keywords
allergies
treatment
nucleic acids
nucleic
acids
Prior art date
Application number
PL12878776T
Other languages
English (en)
Polish (pl)
Inventor
William Hearl
Teri Heiland
Original Assignee
Immunomic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics, Inc. filed Critical Immunomic Therapeutics, Inc.
Publication of PL2861240T3 publication Critical patent/PL2861240T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PL12878776T 2012-06-15 2012-06-15 Kwasy nukleinowe do leczenia alergii PL2861240T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies
EP12878776.9A EP2861240B1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Publications (1)

Publication Number Publication Date
PL2861240T3 true PL2861240T3 (pl) 2021-07-05

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12878776T PL2861240T3 (pl) 2012-06-15 2012-06-15 Kwasy nukleinowe do leczenia alergii

Country Status (20)

Country Link
US (3) US9744230B2 (enExample)
EP (2) EP3808361A1 (enExample)
JP (1) JP5807994B2 (enExample)
KR (2) KR102386481B1 (enExample)
CN (2) CN107937423A (enExample)
AU (3) AU2012382406B2 (enExample)
BR (1) BR112014031327B1 (enExample)
CA (1) CA2876824C (enExample)
CY (1) CY1123769T1 (enExample)
DK (1) DK2861240T3 (enExample)
ES (1) ES2831723T3 (enExample)
HR (1) HRP20201815T1 (enExample)
HU (1) HUE052481T2 (enExample)
IL (4) IL236174B (enExample)
LT (1) LT2861240T (enExample)
PL (1) PL2861240T3 (enExample)
PT (1) PT2861240T (enExample)
RS (1) RS61098B1 (enExample)
SI (1) SI2861240T1 (enExample)
WO (1) WO2013187906A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
HUE052481T2 (hu) 2012-06-15 2021-04-28 Immunomic Therapeutics Inc Nukleinsavak, allergiák kezelésére
DK2914286T3 (da) 2012-10-30 2021-11-08 Aravax Pty Ltd Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf
KR20160075532A (ko) 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
CN106459994A (zh) * 2014-06-23 2017-02-22 免疫治疗有限公司 用于治疗花生过敏的核酸
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
JP6697562B2 (ja) 2015-12-23 2020-05-20 メディジーン イミュノテラピーズ ゲーエムベーハー 樹状細胞組成物
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
WO2018195527A1 (en) * 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
US11382934B2 (en) 2017-07-18 2022-07-12 Before Brands, Inc. Methods for making mixed allergen compositions
WO2019194656A1 (ko) * 2018-04-06 2019-10-10 (주)에스엘에스바이오 신규한 면역글로불린 e의 에피토프, 그와 결합하는 항체 및 상기 항체를 포함하는 시료 중 면역글로불린 e를 분석하기 위한 키트
CA3099495A1 (en) * 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating mite allergy
WO2019216396A1 (ja) * 2018-05-11 2019-11-14 アステラス製薬株式会社 甲殻類アレルギー治療のための核酸
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
CA3127337A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
JP7266700B2 (ja) * 2019-03-13 2023-04-28 プソマーゲン， インコーポレイテッド アレルギー治療のためのエピトープベースアプローチ及びクローン病のための阻害薬
EP4333807A1 (en) * 2021-05-04 2024-03-13 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
AU2022321126A1 (en) * 2021-08-06 2024-02-29 Kao Corporation Nucleic acid structure utilizing snare
FI20237105A1 (en) 2023-05-29 2024-11-30 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic action and greater survival

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
AU5668194A (en) * 1992-11-12 1994-06-08 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
JPH11507840A (ja) 1995-12-29 1999-07-13 ユニバーシティ オブ アーカンソー ピーナッツアレルゲンおよび方法
DE69737659T2 (de) 1996-06-14 2007-12-27 Meiji Dairies Corp. Peptide aus t-zellepitopen
EP1278550A4 (en) * 2000-04-07 2004-05-12 Univ California SYNERGISTIC IMPROVEMENTS OF POLYNUCLEOTIDE VACCINE
WO2002074250A2 (en) 2001-03-16 2002-09-26 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
ES2404689T3 (es) 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
WO2006099574A2 (en) * 2005-03-16 2006-09-21 Tai June Yoo Cockroach allergen gene expression and delivery systems and uses
US20090304738A1 (en) 2005-06-16 2009-12-10 Moran Thomas M Methods for Enhancing Immune Responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
JPWO2007024026A1 (ja) * 2005-08-25 2009-03-05 明石　満 Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
WO2010029317A2 (en) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Treating inflammatory conditions
HUE052481T2 (hu) 2012-06-15 2021-04-28 Immunomic Therapeutics Inc Nukleinsavak, allergiák kezelésére
US11826423B2 (en) * 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
WO2018195527A1 (en) * 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs

Also Published As

Publication number Publication date
CN107937423A (zh) 2018-04-20
LT2861240T (lt) 2021-01-25
US20220081474A1 (en) 2022-03-17
AU2018200625B2 (en) 2019-09-19
BR112014031327A2 (pt) 2017-06-27
CA2876824A1 (en) 2013-12-19
IL270261B (en) 2021-03-25
AU2012382406A2 (en) 2015-04-16
CY1123769T1 (el) 2022-05-27
RS61098B1 (sr) 2020-12-31
US9744230B2 (en) 2017-08-29
CN104519896A (zh) 2015-04-15
KR102107646B1 (ko) 2020-05-08
US20160271245A1 (en) 2016-09-22
AU2018200625A1 (en) 2018-02-15
PT2861240T (pt) 2020-11-09
IL236174B (en) 2019-11-28
HRP20201815T1 (hr) 2021-02-19
EP2861240A1 (en) 2015-04-22
KR20200047792A (ko) 2020-05-07
EP2861240B1 (en) 2020-09-09
HUE052481T2 (hu) 2021-04-28
JP2015521467A (ja) 2015-07-30
AU2019250227B2 (en) 2021-10-21
EP3808361A1 (en) 2021-04-21
CA2876824C (en) 2020-07-21
SI2861240T1 (sl) 2021-04-30
AU2012382406A1 (en) 2014-12-18
KR102386481B1 (ko) 2022-04-14
US20180009857A1 (en) 2018-01-11
DK2861240T3 (da) 2020-09-28
JP5807994B2 (ja) 2015-11-10
KR20150032286A (ko) 2015-03-25
IL270262A (en) 2019-12-31
EP2861240A4 (en) 2016-03-16
WO2013187906A1 (en) 2013-12-19
ES2831723T3 (es) 2021-06-09
IL236174A0 (en) 2015-01-29
AU2012382406B2 (en) 2017-12-07
US10072053B2 (en) 2018-09-11
CN104519896B (zh) 2017-11-10
BR112014031327B1 (pt) 2022-02-01
IL270260B (en) 2020-08-31
AU2019250227A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
IL270260B (en) Nucleic acids for treatment of allergies
IL261563A (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
LT2885010T (lt) Tautopatijos gydymo būdai
EP2864360A4 (en) TARGETED THERAPEUTICS
EP2817421A4 (en) Detection of nucleic acids
EP2931751A4 (en) THERAPEUTIC CD47 ANTIBODIES
EP2921192A4 (en) CATHETER
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
EP2823767A4 (en) CATHETER
EP2884134A4 (en) HEAT REGULATORS
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
EP2926857A4 (en) Catheter
EP3967315C0 (en) AKKERMANSIA MUCINIPHILA FOR THE TREATMENT OF CANCER
EP2814017A4 (en) DRIVER ASSISTING APPARATUS
EP2915815A4 (en) NEW MODIFIED NUCLEIC ACID
DK2943561T3 (da) Fotobioreaktor
DK2802660T3 (da) Nye C5A-bindende nucleinsyrer
IL234606B (en) Novel methods and composition for treatment of disease
DK3062824T3 (da) Telomerase-kodende dna-vaccine
EP2858975A4 (en) FBXO3 INHIBITORS
EP2931176A4 (en) Medical sling
EP2789306A4 (en) TREATMENT SYSTEM
EP2857846A4 (en) Microchip
IL238592B (en) Compounds for treatment of liver diseases
ITRM20120473A1 (it) Use of glycerophosphoinositols for the treatment of septic shock